- Home
- VRCA vs ADVM Comparison
VRCA vs ADVM Comparison
Compare VRCA & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- ADVM
- Stock Information
- Founded
- VRCA 2013
- ADVM 2006
- Country
- VRCA United States
- ADVM United States
- Employees
- VRCA N/A
- ADVM N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VRCA Health Care
- ADVM Health Care
- Exchange
- VRCA Nasdaq
- ADVM Nasdaq
- Market Cap
- VRCA 54.0M
- ADVM 47.4M
- IPO Year
- VRCA 2018
- ADVM 2014
- Fundamental
- Price
- VRCA $0.80
- ADVM $2.56
- Analyst Decision
- VRCA Hold
- ADVM Strong Buy
- Analyst Count
- VRCA 5
- ADVM 5
- Target Price
- VRCA $6.00
- ADVM $23.80
- AVG Volume (30 Days)
- VRCA 672.3K
- ADVM 332.6K
- Earning Date
- VRCA 08-13-2025
- ADVM 08-11-2025
- Dividend Yield
- VRCA N/A
- ADVM N/A
- EPS Growth
- VRCA N/A
- ADVM N/A
- EPS
- VRCA N/A
- ADVM N/A
- Revenue
- VRCA $7,179,000.00
- ADVM $1,000,000.00
- Revenue This Year
- VRCA $171.87
- ADVM N/A
- Revenue Next Year
- VRCA $71.38
- ADVM $18.82
- P/E Ratio
- VRCA N/A
- ADVM N/A
- Revenue Growth
- VRCA N/A
- ADVM N/A
- 52 Week Low
- VRCA $0.38
- ADVM $1.78
- 52 Week High
- VRCA $8.98
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- VRCA 68.47
- ADVM 52.87
- Support Level
- VRCA $0.52
- ADVM $2.19
- Resistance Level
- VRCA $0.67
- ADVM $2.60
- Average True Range (ATR)
- VRCA 0.08
- ADVM 0.23
- MACD
- VRCA 0.03
- ADVM 0.02
- Stochastic Oscillator
- VRCA 70.47
- ADVM 83.52
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.